story of the week
Elranatamab for Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nat. Med. 2023 Aug 15;[EPub Ahead of Print], AM Lesokhin, MH Tomasson, B Arnulf, NJ Bahlis, H Miles Prince, R Niesvizky, P Rodrίguez-Otero, J Martinez-Lopez, G Koehne, C Touzeau, Y Jethava, H Quach, J Depaus, H Yokoyama, AE Gabayan, DA Stevens, AK Nooka, S Manier, N Raje, S Iida, MS Raab, E Searle, E Leip, ST Sullivan, U Conte, M Elmeliegy, A Czibere, A Viqueira, M MohtyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.